Stoke Therapeutics (STOK)
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (85%) **Content type:** Business